Fujian Wanchen Biotechnology Co. Ltd (300972) - Total Assets
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) holds total assets worth CN¥10.76 Billion CNY (≈ $1.57 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Fujian Wanchen Biotechnology Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
Fujian Wanchen Biotechnology Co. Ltd - Total Assets Trend (2019–2025)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's total assets have evolved over time, based on quarterly financial data. Check 300972 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Fujian Wanchen Biotechnology Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Fujian Wanchen Biotechnology Co. Ltd's total assets of CN¥10.76 Billion consist of 88.5% current assets and 11.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 47.2% |
| Accounts Receivable | CN¥13.07 Million | 0.1% |
| Inventory | CN¥2.36 Billion | 23.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥80.97 Million | 0.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300972 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fujian Wanchen Biotechnology Co. Ltd's current assets represent 88.5% of total assets in 2025, an increase from 11.3% in 2019.
- Cash Position: Cash and equivalents constituted 47.2% of total assets in 2025, up from 4.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 23.5% of total assets.
Fujian Wanchen Biotechnology Co. Ltd Competitors by Total Assets
Key competitors of Fujian Wanchen Biotechnology Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sildarvinnslan Hf.
IC:SVN
|
Iceland | Ikr1.08 Billion |
|
Winall Hi tech Seed
SHE:300087
|
China | CN¥6.69 Billion |
|
Hunan New Wellful Co Ltd
SHG:600975
|
China | CN¥11.94 Billion |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
China | CN¥5.09 Billion |
|
Astra Agro Lestari Tbk
JK:AALI
|
Indonesia | Rp30.51 Trillion |
|
Blumar
SN:BLUMAR
|
Chile | CL$1.04 Billion |
|
Salmones Camanchaca S.A
SN:SALMOCAM
|
Chile | CL$458.89 Million |
|
Australian Agricultural Company Ltd
AU:AAC
|
Australia | AU$2.57 Billion |
Fujian Wanchen Biotechnology Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.28 | 1.80 |
| Quick Ratio | 1.17 | 0.93 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.37 Billion | CN¥1.15 Billion | CN¥131.10 Million |
Fujian Wanchen Biotechnology Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Fujian Wanchen Biotechnology Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.38 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 38.5% |
| Total Assets | CN¥10.05 Billion |
| Market Capitalization | $4.97 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Fujian Wanchen Biotechnology Co. Ltd's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fujian Wanchen Biotechnology Co. Ltd's assets grew by 38.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fujian Wanchen Biotechnology Co. Ltd (2019–2025)
The table below shows the annual total assets of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.05 Billion ≈ $1.47 Billion |
+38.52% |
| 2024-12-31 | CN¥7.25 Billion ≈ $1.06 Billion |
+84.78% |
| 2023-12-31 | CN¥3.93 Billion ≈ $574.40 Million |
+226.80% |
| 2022-12-31 | CN¥1.20 Billion ≈ $175.77 Million |
+39.15% |
| 2021-12-31 | CN¥863.18 Million ≈ $126.31 Million |
+31.06% |
| 2020-12-31 | CN¥658.59 Million ≈ $96.37 Million |
+0.45% |
| 2019-12-31 | CN¥655.63 Million ≈ $95.94 Million |
-- |
About Fujian Wanchen Biotechnology Co. Ltd
Fujian Wanchen Biotechnology Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company offers enoki and golden enoki, white jade, crab, seafood, deer antler, oyster, and other mushrooms products, as well as flammulina velutipes, hydrangea edulis, and pleurotus eryngii. It is also inv… Read more